Pharmacokinetics and biodisposition of fluorescein-labeled arabinogalactan in rats

International Journal of Pharmaceutics

Volumn 201, Issue 1, 2000, Pages 59-69

  Kaneo, Yoshiharu ^a   Ueno, Takashi ^a   Tanaka, Tetsuro ^a   Iwase, Hiroki ^a   Yamaguchi, Yasunori ^b   Uemura, Tomochika ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b Laboratory of Animal Cell Technology   (Japan)

Author keywords

Arabinogalactan; Asialoglycoprotein receptor; Biodisposition; FITC; Fluorescence microscopy; Glycotargeting; Hepatotropic carrier; High performance size exclusion chromatography; Pharmacokinetics; Rat

Indexed keywords

ALDEHYDE; ARABINOGALACTAN; ASIALOFETUIN; ASIALOGLYCOPROTEIN RECEPTOR; DIMETHYL SULFOXIDE; DRUG CARRIER; FLUORESCEIN ISOTHIOCYANATE; PERIODATE; SCHIFF BASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG LIVER LEVEL; DRUG OXIDATION; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG UPTAKE; DRUG URINE LEVEL; ENDOCYTOSIS; FLUORESCENCE MICROSCOPY; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERNALIZATION; KIDNEY; LIVER CELL; LIVER PARENCHYMA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; AREA UNDER CURVE; BILE; CELL SEPARATION; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FECES; FLUORESCEINS; FLUORESCENT DYES; GALACTANS; KIDNEY; LIVER; MALE; RATS; RATS, WISTAR; RECEPTORS, DRUG; TISSUE DISTRIBUTION;

EID: 0034658553     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(00)00405-1     Document Type: Article

References (26)

1. Adams M.K., Douglas C. Arabinogalactan - a review of the literature. Tech. Assoc. Pulp Paper Ind. 46:1963;544-548.
2. Ashwell G., Morell A.G. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Advan. Enzymol. 41:1974;99-128.
3. Bernstein A., Hurwitz E., Maron R., Arnon R., Sela M., Wilechek M. Higher antitumor efficacy of daunomycin when linked to dextran: in vivo and in vitro studies. J. Natl. Cancer Inst. 60:1978;379-384.
4. Campbell L.A. Pharmaceutical aspects of a p-aminosalicylate dialdehyde starch compound. J. Pharm. Sci. 52:1963;76-78.
5. Cui L., Faraj A., E1Alaoui A.M., Groman E.V., Rutkowski J.V., Josephson L., Sommadossi J.-P. Arabinogalactan (9 KDa)-9β-D-arabinofuranosyladenine-5′-monophosphate, a novel liver-targeted conjugate that selectively inhibits hepatitis B virus replication in vitro. Antivir. Chem. Chemother. 8:1997;529-536.
6. deBelder A.N., Granath K. Preparation and properties of fluorescein-labelled dextrans. Carbohydr. Res. 30:1973;375-378.
7. DiStefano G., Fiume L. Liver glycotargeting of antiviral nucleoside analogues. Trends Glycosci. Glycotech. 9:1997;461-472.
8. Enriquez P.M., Jung C., Josephson L. Conjugation of adenine arabinoside 5′-monophosphate to arabinogalctan: synthesis, characterization, and antiviral activity. Bioconjugate Chem. 6:1995;195-202.
9. Groman E.V., Enriquez P.M., Jung C., Josephson L. Arabinogalactan for hepatic drug delivery. Bioconjugate Chem. 5:1994;547-556.
10. Josephson L., Groman E.V., Menz E., Lewis L.M., Bengele H. A functionalized superparamagnetic iron oxide colloid as a receptor directed MR contrast agent. Magn. Reson. Imaging. 8:1990;637-646.
11. Kurtzhals R., Larsen C., Johansen M. High-performance size-exclusion chromatographic procedure for the determination of fluoresceinyl isothiocyanate dextrans of various molecular masses in biological media. J. Chromatogr. 491:1989;117-127.
12. Larsen C. Dextran prodrugs-structure and stability in relation to therapeutic activity. Adv. Drug Deliv. Rev. 3:1989;103-154.
13. Mehvar R., Shepard T.L. Molecular-weight-dependent pharmacokinetics of fluorescein-labeled dextrans in rats. J. Pharm. Sci. 81:1992;908-912.
14. Meijer D.K.F., Jansen R.W., Molema G. Drug targeting systems for antiviral agents: options and limitations. Antivir. Res. 18:1992;215-258.
15. Monsigny M., Roche A., Midoux P., Mayer R. Glycoconjugates as carriers for specific delivery of therapeutic drugs and genes. Adv. Drug Deliv. Rev. 14:1994;1-24.
16. Mu J.-Z., Tang L.-H., Alpers D.H. Asialoglycoprotein receptor mRNAs are expressed in most extrahepatic rat tissues during development. Am. J. Physiol. 264:1993;G752-762.
17. Naim J.O., vanOss C.J. The effect of hydrophilicity-hydrophobicity and solubility on the immunogenicity of some natural and synthetic polymers. Immunol. Invest. 21:1992;649-662.
18. Odonmazig P., Ebringerova A., Machova E., Alfoldi J. Structural and molecular properties of the arabinogalactan isolated from Mongolian larchwood. Carbohydr. Res. 252:1994;317-324.
19. Seglen P.O. Preparation of isolated liver cells. Methods Cell Biol. 13:1976;29-83.
20. Singh M., Ray A.R., Vasudevan P. Biodegradation studies on periodate oxidized cellulose. Biomaterial. 3:1982;16-20.
21. Takakura Y., Fujita T., Hashida M., Sezaki H. Disposition characteristics of macromolecules in tumor-bearing mice. Pharm. Res. 7:1990;339-346.
22. Uhlenbruck G., Beuth J., Oette K., Ko H.L., Pulverer G. Prevention of experimental liver metastases by D-galactose. Experientia. 43:1987;437-438.
23. Wadhwa M.S., Rice K.G. Receptor mediated glycotargeting. J. Drug Target. 3:1995;111-127.
24. Weissleder R., Reimer P., Lee A.S., Wittenberg J., Brady T.J. MR receptor imaging: ultrasmall iron oxide particles targeted to asialoglycoprotein receptors. Am. J. Roentgenol. 155:1990;1161-1167.
25. Wileman T., Bennett M., Lilleymann J. Potential use of an asparaginase-dextran conjugate in acute lymphoblastic leukaemia. J. Pharm. Pharmacol. 35:1983;762-765.
26. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharm. Dyn. 4:1981;879-885.